WTC
TPST icon

WhitTier Trust Company’s Tempest Therapeutics TPST Stock Holding History

WhitTier Trust Company’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$42 – 1302
2024
Q1 		$42 Hold
1
– – ﹤0.01% 1215
2023
Q4 		$47 Buy
+1
New +$47 ﹤0.01% 1197

Other funds holding TPST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

WhitTier Trust Company's TPST Position: Q2 2024 in Review

WhitTier Trust Company sold out of Tempest Therapeutics (TPST) in Q2 2024, closing a stake of 1 share — an estimated $42 sold.

WhitTier Trust Company first reported a position in TPST in Q4 2023 and held it in 2 quarters. The position peaked at $47 in Q4 2023. 24 funds tracked by Wall St. Rank hold TPST as of Q2 2024.

  • WhitTier Trust Company reported no remaining Tempest Therapeutics position as of Q2 2024 after selling out during the quarter.
  • WhitTier Trust Company sold 1 Tempest Therapeutics share in Q2 2024, an estimated $42.
  • WhitTier Trust Company first reported a position in Tempest Therapeutics in Q4 2023 and held it in 2 quarters.
  • WhitTier Trust Company's Tempest Therapeutics position peaked at $47 in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2024.

Based on WhitTier Trust Company's 13F filing for Q2 2024, filed 29 Jul 2024.